glp 1 health risks GLP-1 Agonists In Obesity Ozempic and GLP-1 Drugs: Risk

For weight management, Wegovy (semaglutide) and Saxenda (liraglutide) are licensed for adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbidities

But over the last few years a class of medicines originally developed to treat type 2 diabetes has shown dramatic effects on body weight

Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB, et al

Retatrutide activates three hormone receptors at once: GLP-1R (reduces appetite, stimulates insulin), GIPR (boosts insulin and modulates appetite via a separate brain pathway), and GCGR (increases calorie burning and fat breakdown)

Eli Lilly partnered with Fauna Bio to explore novel targets beyond GLP-1s, looking for ways to help humans maintain healthy metabolism during weight loss

HRT is typically continued for as long as symptoms persist and benefits outweigh risks